abstract |
According to the present disclosure, a pharmaceutical composition comprising an antibody having ADCC activity, a T cell redirecting antibody, or a cell expressing a chimeric receptor for use in combination with administration of an antigen-binding molecule capable of binding to a target antigen, The primary molecule includes a linker cleaved by a protease, and the antigen-binding molecule in which the linker is cleaved has the ability to bind to a target antigen and has ADCC activity or a variable region of an antibody or T cell redirecting antibody, and a chimeric receptor The above pharmaceutical composition is provided, wherein the extracellular binding domain of the cleaved linker binds to a cell expressing a target antigen via binding to the cleaved antigen-binding molecule by a linker generated after cleavage of the linker. |